ArticleJournal of nanobiotechnology2026
Degradable scaffold-mediated synergistic matrix formation by endogenous cells: an in vivo manufacturing strategy for off-the-shelf vascular grafts to address clinical shortages.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vascular bypass surgery is an important treatment for severe atherosclerosis, but the scarcity of autologous blood vessels restricts its clinical application. Although tissue-engineered vascular grafts (TEVGs) have potential, the long cycle of traditional in vitro culture makes it difficult to achieve “off-the-shelf” supply. This study innovatively proposes a strategy of guiding the in vivo self-assembly of endogenous cells via degradable scaffolds to rapidly construct Vascular bypass grafts. After implanting electrospun PLCL nanofibrous elastomer scaffolds subcutaneously in SD rats, host fibroblasts, and abdominal adipose-derived stem cells were recruited in two weeks. These cells synergistically secreted extracellular matrix, forming an endogenous cell-empowered tissue-engineered PLCL (TE-P) vascular graft. The graft has appropriate stress relaxation and creep properties, and can support the adhesion and migration of arterial endothelial cells. In the abdominal aorta replacement model, TE-P remained patent 90 days after transplantation, with the vessel wall having synchronous contraction function and elasticity, and the effect of tissue structure reconstruction was close to that of the “gold standard” autologous blood vessels. Transcriptome analysis showed that TE-P promotes vascular regeneration through the synergistic mechanisms of energy metabolism, immune balance, cell fate regulation, and matrix remodeling. This conclusion was verified by immunofluorescence, transmission electron microscopy, and flow cytometry. The scalable platform established in this study realizes the rapid in vivo manufacturing of off-the-shelf Vascular bypass grafts through the self-assembly of endogenous cells, making its production cycle match the time window of elective surgery, and providing a new solution to break through the bottleneck of clinical shortage of transplant vessels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.